New hope for rare stomach cancer: targeted drug trial begins
NCT ID NCT07434843
First seen Feb 28, 2026 · Last updated Jun 15, 2026 · Updated 20 times
Summary
This study tests a drug called pemigatinib in 24 people with a rare, advanced stomach cancer called SDH-deficient GIST that cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the disease. Researchers will also monitor side effects to understand how well patients tolerate the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.